Table 1. Characteristics of healthy controls and patients.
| Controls (n=20) | ECT (n=24)a | Ketamine (n=16)b | P-value | |
|---|---|---|---|---|
| Age | 42.85±2.22 | 56.88±2.75 | 44.63±3.40 | Control vs ECT: P<0.01 ECT vs KET: P<0.01 |
| Gender | 11M, 9F | 9M, 15F | 10M, 6F | NS |
| Baseline HDRS | — | 22.42±0.90 | 21.38±0.75 | NS |
| Post-treatment HDRS | — | 9.26±1.26 | 7.15±0.84 | NS |
| Responder | 5.67±0.78 (15/23) | 6.36±0.76 (11/13) 5.2±0.58 (5/11 long-term responders) | NS | |
| Non-responder | 16.00±1.49 (8/23) | 11.00±4.00 (2/13) | NS | |
| Medication profilec | ||||
| Selective serotonin reuptake inhibitor | 3 | 5 | ||
| Selective noradrenaline reuptake inhibitor | 8 | 4 | ||
| Serotonin agonist and reuptake inhibitor | 1 | — | ||
| Tricyclic antidepressant | 7 | — | ||
| Noradrenergic and specific serotonergic antidepressant | 4 | 1 | ||
| Monoamine oxidase inhibitor | 1 | — | ||
| Buproprion | 1 | 2 | ||
| Other | 7 | 4 | ||
Abbreviations: ECT, electroconvulsive therapy; F, female; HDRS, Hamilton Depression Rating Scale; KET, ketamine; M, male; NS, not significant.
a
One sample from a patient post-ECT session was unavailable.
b
Three samples from patient post-KET infusion were unavailable.
c
Eight patients in the ECT group were on more than one of antidepressants listed in this table.